Teropavimab Biosimilar – Anti-Surface protein gp120 mAb – Research Grade

Description of Teropavimab Biosimilar - Anti-Surface protein gp120 mAb - Research Grade

Introduction

Teropavimab Biosimilar, also known as Anti-Surface protein gp120 mAb, is a monoclonal antibody that specifically targets the surface protein gp120 of the human immunodeficiency virus (HIV). This biosimilar is a research grade product that has shown promising results in pre-clinical studies and is currently being evaluated for its potential as a therapeutic agent for HIV.

Structure of Teropavimab Biosimilar

Teropavimab Biosimilar is a recombinant monoclonal antibody that is produced using advanced biotechnology techniques. It is a humanized antibody, meaning that it is derived from non-human sources but has been modified to resemble a human antibody. This modification reduces the risk of immune reactions and increases the stability of the antibody.

The antibody has a Y-shaped structure, with two identical heavy chains and two identical light chains. The heavy chains are composed of four constant regions and one variable region, while the light chains have two constant regions and one variable region. The variable regions are responsible for binding to the target antigen, gp120, while the constant regions provide stability and effector functions.

Mechanism of Action

Teropavimab Biosimilar works by binding to the surface protein gp120 of HIV. This protein is essential for the virus to enter and infect human cells. By binding to gp120, Teropavimab Biosimilar prevents the virus from attaching to and entering host cells, thereby inhibiting its replication and spread.

In addition, Teropavimab Biosimilar also has effector functions that can activate the immune system to target and eliminate HIV-infected cells. This makes it a potential candidate for both prevention and treatment of HIV infection.

Applications of Teropavimab Biosimilar

Teropavimab Biosimilar has shown promising results in pre-clinical studies as a potential therapeutic agent for HIV. It has been found to have high specificity and potency in neutralizing HIV and has shown no cross-reactivity with other human proteins.

In addition to its potential as a therapeutic agent, Teropavimab Biosimilar can also be used as a research tool for studying the structure and function of gp120 and its interaction with other proteins. Its high specificity and potency make it a valuable tool for understanding the mechanisms of HIV infection and developing new treatments.

Conclusion

Teropavimab Biosimilar, also known as Anti-Surface protein gp120 mAb, is a recombinant monoclonal antibody that specifically targets the surface protein gp120 of HIV. Its unique structure and mechanism of action make it a promising candidate for both prevention and treatment of HIV infection. In addition, its high specificity and potency make it a valuable research tool for studying the virus and developing new treatments. Further clinical studies are needed to fully evaluate the potential of Teropavimab Biosimilar as a therapeutic agent for HIV.

Teropavimab Biosimilar - Anti-Surface protein gp120 mAb binds to HIV1 gp120 / SU recombinant protein in ELISA assay

Immobilized HIV1 gp120 / SU recombinant protein (cat. No. PX-P5202) at 0.5µg/mL (100µL/well) can bind Teropavimab Biosimilar - Anti-Surface protein gp120 mAb (cat. No. PX-TA1793) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 437.5M.